Table 2 Clinical and laboratory characteristics of study group 1.
Feature | All patients (n = 51) | UDCA responders a (n = 21) | UDCA non-responders a (n = 18) | p value b |
|---|---|---|---|---|
Age (years) | 60.4 ± 11.1 | 62.2 ± 14.3 | 60.3 ± 9.1 | 0.6 |
Gender (F/M) | 45/6 | 20/1 | 15/3 | 0.43 |
Cirrhosis (yes/no) | 23/28 | 8/13 | 12/6 | 0.06 |
Hemoglobin (mg/dl) | 13.1 ± 1.5 | 13.7 ± 1.3 | 12.2 ± 1.5 | 0.02 |
ALT (IU/l; Normal:<30) | 71.4 ± 131.0 | 88.6 ± 194.5 | 58.7 ± 37.9 | 0.49 |
AST (IU/l; Normal:<30) | 60.8 ± 57.6 | 55.7 ± 75.2 | 74.7 ± 47.1 | 0.33 |
ALP (IU/l; Normal:<120) | 196.7 ± 149.1 | 111.2 ± 44.5 | 278.9 ± 149.4 | 0.0003 |
GGT (IU/l; Normal:<42) | 219.3 ± 331.8 | 72.8 ± 57.7 | 271.4 ± 232.8 | 0.06 |
Bilirubin (mg/dl; Normal:<1.0) | 1.81 ± 4.5 | 1.1 ± 1.4 | 2.9 ± 6.8 | 0.23 |
Albumin (g/dl; Normal:3.8–4.4) | 4.1 ± 0.5 | 4.3 ± 0.4 | 3.8 ± 0.4 | 0.002 |
INR (Normal: 0.8–1.2) | 1.1 ± 0.3 | 1.1 ± 0.1 | 1.2 ± 0.4 | 0.06 |
Mayo Risk Score for PBC | 5.4 ± 1.6 | 5.0 ± 1.4 | 6.1 ± 1.9 | 0.04 |
Serum FGF19 (pg/ml) | 104.0 ± 152.5 | 67.5 ± 42.9 | 167.0 ± 240.3 | 0.04 |
